The Effect of Alpha Linolenic Acid Intake on Patients With Elevated Glycemic Status

Last updated: September 30, 2025
Sponsor: Huazhong University of Science and Technology
Overall Status: Completed

Phase

N/A

Condition

Diabetes And Hypertension

Diabetes Mellitus, Type 2

Diabetes Mellitus Types I And Ii

Treatment

Corn oil capsule

Flaxseed oil capsule

Clinical Study ID

NCT05053347
JWY20210916
  • Ages 30-65
  • All Genders

Study Summary

The findings of previous experiments suggested that alpha linolenic acid (ALA) has been linked to anti-hyperglycemic, and reducing the risk of diabetes.This is a randomized double-blind cross-over trial, aims to study the effect of ALA on glycemic status and human metabolism. Firstly, the investigators will investigate the efficacy of ALA on improving the indexes of glucose metabolism. Secondly, next generation sequencing (NGS), ultra-high performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) and gas chromatography-mass spectrometry detection will be conducted to explore the role of ALA on gut microbiota as well as metabolites. Thirdly, single nucleotide polymorphism will be genotyped by Time-of-flight mass spectrometry to find the gene-environment interaction effect.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Fasting blood glucose 6.1-8.4mmol /L;

  • HbA1c 5.7-7.0%;

  • Patients with previously diagnosed type 2 diabetes with stable drug hypoglycemictreatment and blood glucose controlled well.

Exclusion

Exclusion Criteria:

  • Under 30 years old or over 75 years old;

  • Suffering from severe metabolic disorders, malignancies, psychiatric conditions;

  • undergoing insulin therapy, or antibiotic/probiotic use for more than threeconsecutive days in the last month.

  • Daily cooking oil is flaxseed oil, rapeseed oil or other α -linolenic acid richvegetable oil;

  • Intake more than 20g walnuts per day or more than 100g fatty fish per week in thelast month;

  • Take nutritional supplements, such as fish oil capsules, perilla seed oil andflaxseed oil capsules, for nearly one month;

  • Allergic to the content of intervention;

  • Failure to eat the tested sample as prescribed and affect the efficacy or safetyjudgment.

Study Design

Total Participants: 94
Treatment Group(s): 2
Primary Treatment: Corn oil capsule
Phase:
Study Start date:
July 01, 2022
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Sinopharm Dongfeng General Hospital

    Shiyan 1794903, Hubei 1806949 442000
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.